Lupin Gains EMA Approval for Pediatric Use of NaMuscla

Global pharmaceutical major Lupin Limited announced today that the European Medicines Agency (EMA) has granted approval for a change to the marketing authorization for NaMuscla (mexiletine). The regulatory green light enables the use of the drug for the symptomatic treatment of myotonia in children aged 6 to 11 years (weighing at least 20 kg) and adolescents aged 12 to 17 years, in addition to the existing adult indication.

This development, supported by the company's Pediatric Investigation Plan (PIP), marks a significant milestone for Lupin in addressing unmet medical needs within rare neuromuscular disorders. The approval also introduces two new capsule dosage strengths—62 mg and 83 mg—which complement the previously authorized 167 mg strength, allowing for more precise dosing in younger patients.

Expanding Access to Rare Disease Care

Non-dystrophic myotonic disorders (NDM) are a group of rare, inherited neuromuscular conditions characterized by myotonia—an inability to relax muscles after voluntary contraction. For patients, this results in significant muscle stiffness, pain, and fatigue, impacting daily activities such as walking or climbing stairs.

"This EMA approval for the pediatric indication of NaMuscla represents a significant step forward for patients and families living with non-dystrophic myotonic disorders—especially children, where options are scarce," said Claus Jepsen, President of Global Specialty at Lupin. The company is now coordinating the rollout of the new dosage strengths across European territories, subject to local implementation timelines and national reimbursement processes.

Regulatory and Clinical Context

The approval process for the pediatric expansion has been a multi-stage effort, with the EMA’s Committee for Medicinal Products for Human Use (CHMP) previously issuing a positive opinion regarding the safety and efficacy of the new dosage forms in March 2026.

NaMuscla functions by blocking sodium channels in muscle cells, which helps reduce the excessive electrical activity that leads to muscle stiffness. By gaining formal regulatory approval for the pediatric population, Lupin aims to shift treatment patterns away from off-label usage toward a standardized, licensed therapy specifically formulated for younger demographics.

Official Sources

The authorization was confirmed in a corporate press release issued by Lupin Limited on July 1, 2026. Regulatory details are documented under the European Medicines Agency's (EMA) centralized marketing authorization procedures for medicinal products.

Why It Matters

For the medical community and patients, this approval provides a critical therapeutic option where few existed. For investors, the milestone strengthens Lupin’s "Specialty and Innovation" portfolio. As a niche orphan drug, NaMuscla’s expanded label provides Lupin with a competitive advantage in the European specialty pharmaceuticals market, bolstering its revenue mix through high-value, orphan-designated therapeutics.

Key Facts at a Glance

• Approval: EMA authorization for pediatric use (6–17 years) of NaMuscla.

• New Strengths: 62 mg and 83 mg capsules added to the existing 167 mg.

• Indication: Symptomatic treatment of myotonia in non-dystrophic myotonic disorders.

• Target Group: Children (6–11 years, ≥20 kg), adolescents (12–17 years), and adults (≥18 years).

• Active Ingredient: Mexiletine hydrochloride.

Frequently Asked Questions

What is NaMuscla used for? NaMuscla is an orphan drug indicated for the symptomatic treatment of myotonia (muscle stiffness) in patients with non-dystrophic myotonic disorders.

How do the new 62 mg and 83 mg capsules help patients? The new, smaller dosage strengths allow healthcare professionals to tailor the medication more accurately to the body weight of pediatric patients, ensuring safer and more effective treatment.

When will the new pediatric dosages be available in Europe? Lupin is working to make these new dosage strengths available across Europe; availability will depend on local implementation timelines and national access/reimbursement processes.

Source: Lupin Limited Press Release, European Medicines Agency (EMA), Business Standard Markets